We invite those 18 to 85 years old who are experiencing involuntary movements in their face or other parts of their body – and suffer from a gastrointestinal disorder (including trouble with reflux and/or gastric emptying) – to see if they may qualify for the Kinect 2 Study. The purpose of this clinical research study is to determine the safety and effectiveness of an investigational oral medication for tardive dyskinesia.
Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available.
Upon enrollment in the study, participants will be required to complete a screening period prior to receiving their first dose of study medication and a study treatment period of up to 6 weeks (which includes three in-office visits and a follow-up appointment two weeks after completing treatment). Throughout the study, participants will continue to receive regular general health check-ups and monitoring of TD symptoms.